Erudio Healtherudio.com
Sponsor
Stemline Therapeutics trials: what clinicians said in public
No HCP commentary report on a trial sponsored by Stemline Therapeutics yet. Erudio has found public clinician commentary on 4 clinical trials sponsored by Stemline Therapeutics: ELECTRA, NCT02113982, NCT02268253 and TRILLIUM. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (Stemline Therapeutics, Inc.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ELECTRA NCT05386108 · Stemline Therapeutics, Inc. DeepView → | ER+/HER2- breast cancer with brain metastasis | Phase 1/Phase 2 | Deep | View | |||
| NCT02113982 NCT02113982 · Stemline Therapeutics, Inc. FocusedView → | blastic plasmacytoid dendritic cell neoplasm or AML | Phase 1/Phase 2 | Focused | View | |||
| NCT02268253 NCT02268253 · Stemline Therapeutics, Inc. FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| TRILLIUM NCT06456463 · Stemline Therapeutics, Inc. FocusedView → | previously untreated CD123+ AML ineligible for intensive chemotherapy | Phase 2 | Focused | View | |||